Sensitivity analyses
| Change in P1NP, μg/L | P value | Change in CTX, mg/L | P value | |
| Original study arms | ||||
| 4000 IU/day (n=16) | 1.5 (−13.8 to 4.4) | 0.93 | 9.0 (−43.5 to 74.0) | 0.33 |
| 2000 IU/day (n=12) | −0.4 (−2.9 to 6.7) | −8.5 (−45.5 to 8.0) | ||
| Placebo (n=15) | −1.1 (−6.8 to 13.0) | −37.0 (−74.0 to 34.0) | ||
| Vitamin D repletion achieved | ||||
| Yes (n=13) | 1.5 (−0.5 to 5.3) | 0.40 | −3.0 (−48.0 to 10.0) | 0.74 |
| No (n=30) | −1.2 (−8.3 to 8.4) | −2.5 (−52.0 to 34.0) | ||
| Using glucocorticoids at baseline | ||||
| Vitamin D (n=12) | −0.4 (−5.1 to 7.1) | 0.96 | 8.0 (−35.0 to 15.5) | 0.33 |
| Placebo (n=5) | −1.2 (−6.8 to 3.8) | −37.0 (−52.0 to −11.0) | ||
| Not using glucocorticoids at baseline | ||||
| Vitamin D (n=16) | 0.6 (−8.6 to 3.8) | 0.73 | −1.0 (−58.5 to 43.5) | 0.90 |
| Placebo (n=10) | 0.3 (−4.9 to 13.0) | −10.0 (−74.0 to 46.0) | ||
| Interferon signature detectable at baseline | ||||
| Vitamin D (n=25) | −0.5 (−8.3 to 2.2) | 0.52 | 1.0 (−48.0 to 14.0) | 0.22 |
| Placebo (n=11) | −1.2 (−6.8 to 13.2) | −40.0 (−84.0 to 34.0) | ||
| Interferon signature undetectable at baseline | ||||
| Vitamin D (n=3) | 15.8 (10.8 to 16.1) | 0.16 | 31.0 (−39.0 to 364.0) | 0.87 |
| Placebo (n=4) | 0.3 (−5.0 to 7.4) | 22.0 (−27.0 to 493.5) | ||
| Subjects not using bisphosphonates at baseline | ||||
| Vitamin D (n=25) | −0.2 (−4.0 to 4.1) | 0.63 | 6.0 (−39.0 to 17.0) | 0.51 |
| Placebo (n=14) | 0.3 (−4.9 to 13.0) | −38.5 (−74.0 to 34.0) | ||
P values from Kruskal-Wallis test for three-group comparison and Wilcoxon rank-sum test for two-group comparisons.